{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T04:28:38Z","timestamp":1727065718718},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,11,1]]},"DOI":"10.2169\/internalmedicine.8554-21","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T22:10:14Z","timestamp":1649455814000},"page":"3281-3285","source":"Crossref","is-referenced-by-count":3,"title":["Pembrolizumab-induced Myasthenia Gravis Relapse after Immunosuppressive Therapy"],"prefix":"10.2169","volume":"61","author":[{"given":"Yuki","family":"Oshima","sequence":"first","affiliation":[{"name":"Department of Neurology, Hakodate Municipal Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hakodate Municipal Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hakodate Municipal Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376: 1015-1026, 2017.","DOI":"10.1056\/NEJMoa1613683"},{"key":"2","unstructured":"2. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36: 1714-1768, 2018."},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89: 1127-1134, 2017.","DOI":"10.1212\/WNL.0000000000004359"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Johansen A, Christensen SJ, Scheie D, H\u00f8jgaard JLS, Kondziella D. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review. Neurology 92: 663-674, 2019.","DOI":"10.1212\/WNL.0000000000007235"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28: 119-142, 2017.","DOI":"10.1093\/annonc\/mdx225"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Huang Y T, Chen YP, Lin WC, Su WC, Sun YT. Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol 11: 634, 2020.","DOI":"10.3389\/fneur.2020.00634"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7: 319, 2019.","DOI":"10.1186\/s40425-019-0774-y"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Verma N, Jaffer M, Pina Y, Peguero E, Mokhtari S. Rituximab for immune checkpoint inhibitor myasthenia gravis. Cureus 13: e16337, 2021.","DOI":"10.7759\/cureus.16337"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yanase T, Moritoki Y, Kondo H, Ueyama D, Akita H, Yasui T. Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: a case report of successful management. Urol Case Rep 34: 101508, 2020.","DOI":"10.1016\/j.eucr.2020.101508"},{"key":"10","unstructured":"10. Tanaka R, Sunada Y, Fujimoto W, Tanaka R. Successful reinstitution of nivolumab in combination with corticosteroids for metastatic malignant melanoma with myasthenia gravis as an immune-related adverse event. Kawasaki Med J 43: 59-61, 2017."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Santini FC, Rizvi H, Plodkowski AJ, et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res 6: 1093-1099, 2018.","DOI":"10.1158\/2326-6066.CIR-17-0755"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis 76: 681-687, 2017.","DOI":"10.1136\/annrheumdis-2016-210198"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/21\/61_8554-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T03:21:09Z","timestamp":1667618469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/21\/61_8554-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":12,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8554-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]},"article-number":"8554-21"}}